SA
SABS.US SAB Biotherapeutics Inc
- Market cap
- USD 270M
- P/E
- -
- P/B
- 1.26x
- ROE
- -40.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SABS.US undervalued?
Graham numberThe Graham number of SAB Biotherapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
SAB Biotherapeutics Inc fundamental analysis
No fundamental analysis for SAB Biotherapeutics Inc yet.
SAB Biotherapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About SAB Biotherapeutics Inc
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartere…
Full company profileSAB Biotherapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
SAB Biotherapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 3.44M | 55.2M | 60.9M | 23.9M | 2.24M | 1.32M | 0.00 | 0.00 |
| Gross Profit | 3.44M | 55.2M | 59.2M | 20.6M | -1.51M | -3.47M | -3.08M | - |
| Operating Income | -8.67M | 20.6M | -13.4M | -28.9M | -38.1M | -42.9M | -49.0M | -92.4M |
| EBITDA | -8.23M | 21.1M | -15.2M | -15.1M | -38.1M | -29.0M | 16.6M | -86.3M |
| Net Income | -8.99M | 20.1M | -17.1M | -18.7M | -42.2M | -34.1M | 13.3M | -84.9M |
| EPS | -2.07 | 7.45 | -6.27 | -4.31 | -7.64 | -3.68 | 0.22 | -0.91 |
| Balance Sheet | ||||||||
| Total Assets | 18.0M | 56.5M | 81.1M | 50.9M | 83.9M | 44.2M | 173M | 236M |
| Total Liabilities | 20.3M | 17.5M | 42.6M | 19.8M | 26.6M | 18.2M | 21.3M | 24.7M |
| Shareholders' Equity | -2.31M | 39.0M | 38.5M | 31.1M | 57.3M | 26.0M | 151M | 211M |
| Cash & Short-term Investments | 6.35M | 12.6M | 33.2M | 15.0M | 56.6M | 20.8M | 96.6M | 104M |
| Total Debt | 7.64M | 8.13M | 8.52M | 5.93M | 5.91M | 4.67M | 5.95M | 4.92M |
| Cash Flow | ||||||||
| Operating Cash Flow | -9.21M | 10.0M | 1.99M | -23.5M | -25.1M | -34.3M | -44.8M | -68.5M |
| Capital Expenditure | 609K | 12.7M | 10.9M | 2.17M | 197K | 337K | 933K | 6.53M |
| Free Cash Flow | -9.82M | -2.73M | -8.96M | -25.6M | -25.3M | -34.6M | -45.7M | -75.1M |
| Ratios | ||||||||
| ROE | - | 51.6% | -44.5% | -60.3% | -73.6% | -131.3% | 8.8% | -40.2% |
| ROA | -49.9% | 35.6% | -21.1% | -36.8% | -50.3% | -77.2% | 7.7% | -36.0% |
| Net Profit Margin | -261.1% | 36.4% | -28.2% | -78.4% | -1,884.5% | -2,579.0% | - | - |
| Debt to Equity | - | 0.21x | 0.22x | 0.19x | 0.10x | 0.18x | 0.04x | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
SAB Biotherapeutics Inc dividends
SAB Biotherapeutics Inc has not paid dividends in the last 7 fiscal years.
Last stock split: 1:10 on Jan 5, 2024.
Who owns SAB Biotherapeutics Inc
- Insiders 3.15%
- Institutions 84.15%
- Public & others 12.70%
- Shares outstanding 90.1M
- Free float 59.3M
Top funds holding SABS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 2.26M | 2.48% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 1.28M | 1.40% | 0.00% | Oct 2026 |
| iShares Russell 2000 Value ETF | 487K | 0.53% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 474K | 0.52% | 0.00% | Aug 2026 |
| Vanguard Russell 2000 ETF | 318K | 0.35% | +27.51% | Sep 2026 |
| Fidelity Extended Market Index | 297K | 0.33% | +7.04% | Sep 2026 |
| iShares Micro-Cap ETF | 168K | 0.18% | 0.00% | Oct 2026 |
| Schwab Small Cap Index | 134K | 0.15% | +26.36% | Sep 2026 |
| Fidelity Total Market Index | 125K | 0.14% | -0.05% | Sep 2026 |
| Avantis US Small Cap Equity ETF | 114K | 0.13% | +0.82% | Oct 2026 |
| Bridge Builder Small Cap Fund | 112K | 0.12% | 0.00% | Oct 2026 |
| ALPS Medical Breakthroughs ETF | 111K | 0.12% | 0.00% | Oct 2026 |
| Simplify Propel Opportunities ETF | 105K | 0.12% | 0.00% | Oct 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 96.8K | 0.11% | +19.30% | Sep 2026 |
| Fidelity Series Total Market Index | 86.2K | 0.09% | 0.00% | Sep 2026 |
| Fidelity Small Cap Value Index | 64.4K | 0.07% | +2.50% | Aug 2026 |
| Nuveen Small Cap Blend Idx R6 | 58.4K | 0.06% | 0.00% | Sep 2026 |
Top institutions holding SABS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Caligan Partners LP | 7.97M | 8.74% | 0.00% | Jun 2026 |
| Vivo Capital, LLC | 7.30M | 8.01% | -36.08% | Jun 2026 |
| Perceptive Advisors LLC | 6.63M | 7.27% | +3.04% | Jun 2026 |
| Adage Capital Partners Gp LLC | 6.41M | 7.03% | +88.09% | Jun 2026 |
| RA Capital Management, LLC | 4.40M | 4.83% | 0.00% | Jun 2026 |
| Balyasny Asset Management LLC | 3.76M | 4.13% | 0.00% | Jun 2026 |
| BlackRock Inc | 3.07M | 3.36% | +917.51% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.97M | 3.26% | +19.22% | Jun 2026 |
| COMMODORE CAPITAL LP | 2.87M | 3.15% | -34.80% | Jun 2026 |
| Millennium Management LLC | 2.75M | 3.02% | -9.35% | Jun 2026 |
| Spruce Street Capital LP | 2.20M | 2.41% | 0.00% | Jun 2026 |
| Sanofi | 2.20M | 2.41% | 0.00% | Sep 2026 |
| Sessa Capital, L.P | 2.20M | 2.41% | 0.00% | Jun 2026 |
| Affinity Asset Advisors, LLC | 1.53M | 1.67% | +165.22% | Jun 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | 1.48M | 1.63% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 1.28M | 1.40% | +322.86% | Jun 2026 |
| Woodline Partners LP | 1.18M | 1.30% | -58.61% | Jun 2026 |
| Ensign Peak Advisors Inc | 1.17M | 1.29% | -14.75% | Jun 2026 |
| Propel Bio Management LLC | 1.08M | 1.18% | +6.30% | Jun 2026 |
| Soleus Capital Management, L.P. | 900K | 0.99% | -14.29% | Jun 2026 |
SAB Biotherapeutics Inc company profile
- Company name
- SAB Biotherapeutics Inc
- Ticker
- SABS.US
- Exchange
- USA Stocks
- Listed since
- Feb 9, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 86
- Fiscal year end
- December
- Address
- 777 W 41st St., Miami Beach, FL, United States, 33140
- Phone
- 305 845 2813
- Website
- sab.bio
About SAB Biotherapeutics Inc
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
SAB Biotherapeutics Inc management
9- Mr. Samuel J. ReichCEO & Director · born 1975
- Dr. Eddie Joe Sullivan Ph.D.Co-Founder, President & Director · born 1967
- Ms. Lucy ToExecutive VP & CFO · born 1986
- Dr. Christoph Bausch M.B.A., Ph.D.Executive VP & COO · born 1971
- Dr. Alexandra Kropotova M.B.A., M.D.Executive VP & Chief Medical Officer · born 1973
- Ms. Catherine DeRoseVice President of Human Resources
- Ms. Hua Wu Ph.D.Senior Vice President of Product Development
- Dr. Carlos N. Carillo M.Sc., Ph.D.Senior Vice President of Regulatory Affairs
- Ms. Angie ParizekSenior Vice President of Clinical Operations